Targeted Molecular Therapeutics for Parkinson's Disease: A Role for Antisense Oligonucleotides?

被引：2
|
作者：
Li, Dunhui [1 ,2 ,3 ]
Mastaglia, Frank L. [1 ,2 ]
Yau, Wai Yan [1 ]
Chen, Shengdi [4 ,5 ]
Wilton, Steve D. [1 ,2 ]
Akkari, Patrick A. [1 ,2 ,6 ]
机构：
[1] Univ Western Australia, Perron Inst Neurol & Translat Sci, 8 Verdun St, Nedlands, WA 6009, Australia
[2] Murdoch Univ, Ctr Mol Med & Innovat Therapeut, Murdoch, WA, Australia
[3] Zhengzhou Univ, Coll Nursing & Hlth, Zhengzhou, Peoples R China
[4] Shanghai Jiao Tong Univ, Ruijin Hosp, Dept Neurol, Sch Med, Shanghai, Peoples R China
[5] Shanghai Jiao Tong Univ, Ruijin Hosp, Inst Neurol, Sch Med, Shanghai, Peoples R China
[6] Duke Univ, Dept Neurol, Durham, NC USA
来源：
MOVEMENT DISORDERS | 2022年 / 37卷 / 11期
基金：
中国国家自然科学基金;
关键词：
D O I：
10.1002/mds.29201
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
[No abstract available]
引用
收藏
页码：2184 / 2190
页数：7
相关论文
共 50 条
  • [1] TARGETED DELIVERY OF ANTISENSE OLIGONUCLEOTIDES BY MOLECULAR CONJUGATES
    BUNNELL, BA
    ASKARI, FK
    WILSON, JM
    SOMATIC CELL AND MOLECULAR GENETICS, 1992, 18 (06) : 559 - 569
  • [2] α-Synuclein antisense oligonucleotides as a disease-modifying therapy for Parkinson's disease
    Cole, Tracy A.
    Zhao, Hien
    Collier, Timothy J.
    Sandoval, Ivette
    Sortwell, Caryl E.
    Steece-Collier, Kathy
    Daley, Brian F.
    Booms, Alix
    Lipton, Jack
    Welch, Mackenzie
    Berman, Melissa
    Jandreski, Luke
    Graham, Danielle
    Weihofen, Andreas
    Celano, Stephanie
    Schulz, Emily
    Cole-Strauss, Allyson
    Luna, Esteban
    Quach, Duc
    Mohan, Apoorva
    Bennett, C. Frank
    Swayze, Eric E.
    Kordasiewicz, Holly B.
    Luk, Kelvin C.
    Paumier, Katrina L.
    JCI INSIGHT, 2021, 6 (05)
  • [3] Antisense oligonucleotides as therapeutics for hyperlipidaemias
    Crooke, RM
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2005, 5 (07) : 907 - 917
  • [4] Antisense oligonucleotides as therapeutics and their delivery
    Gurav, Bhagyashree
    Srinivasan, Ganga
    CURRENT SCIENCE, 2017, 112 (03): : 490 - 498
  • [5] RNA Targeting Therapeutics: Molecular Mechanisms of Antisense Oligonucleotides as a Therapeutic Platform
    Bennett, C. Frank
    Swayze, Eric E.
    ANNUAL REVIEW OF PHARMACOLOGY AND TOXICOLOGY, 2010, 50 : 259 - 293
  • [6] Antisense oligonucleotides as therapeutics for malignant diseases
    Ho, PTC
    Parkinson, DR
    SEMINARS IN ONCOLOGY, 1997, 24 (02) : 187 - 202
  • [7] 2′-modified oligonucleotides for antisense therapeutics
    Prakash, Thazha P.
    Bhat, Balkrishen
    CURRENT TOPICS IN MEDICINAL CHEMISTRY, 2007, 7 (07) : 641 - 649
  • [8] Synthetic oligonucleotides: The development of antisense therapeutics
    Monteith, DK
    Levin, AA
    TOXICOLOGIC PATHOLOGY, 1999, 27 (01) : 8 - 13
  • [9] Snca Targeted Antisense Oligonucleotides Modulate Progression of Pathological Deposition in alpha Synuclein Rodent Transmission Models of Parkinson's Disease
    Cole, Tracy A.
    Paumier, Katrina
    Collier, Tim
    Blooms, Alix
    Celano, Stephanie
    Schulz, Emily
    Strauss, Allison
    Daley, Brian
    Zhao, Hien
    Weihofen, Andreas
    Kordasiewicz, Holly
    Swayze, Eric
    ANNALS OF NEUROLOGY, 2017, 82 : S55 - S55
  • [10] Snca targeted antisense oligonucleotides mediate progression of pathological deposition in alpha synuclein rodent transmission models of Parkinson's disease
    Cole, Tracy
    Paumier, Katrina
    Zhao, Hien
    Weihofen, Andreas
    Kordasiewicz, Holly
    Swayze, Eric
    NEUROLOGY, 2016, 86
12345